Second-Source GMP Drug Substance Supply for a Systemically Administered AAV Gene Therapy: Scientific, Quality, and Regulatory Rationale for a Technology Transfer Campaign

Adeno-associated virus (AAV) vectors have made systemic gene replacement feasible for diseases of muscle and other tissues, but the doses required, commonly in the range of 10 to the power of 13 to 10 to the power of 14 vector genomes per kilogram, convert every patient into a manufacturing problem. This article develops the scientific, quality, and regulatory rationale for qualifying a second drug substance manufacturing site for a hypothetical licensed, systemically administered AAV gene therapy produced by transient transfection of suspension HEK293 cells. It reviews why the payload problem led to engineered transgenes, how AAV manufacturing science defines the critical quality attributes that govern a site transfer (full-to-empty capsid ratio, residual nucleic acids, potency), and what ICH Q5E, FDA comparability guidance, and 21 C.F.R. 601.12 require of a manufacturing change to a licensed biologic. Four alternatives are compared, and a technology transfer with three conformance lots is shown to be the proportionate next step. A companion article converts this rationale into a request for proposal.Keywords: AAV gene therapy; drug substance; second-source manufacturing; comparability; ICH Q5E; potency assurance; capsid quality

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24425187
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Second-Source GMP Drug Substance Supply for a Systemically Administered AAV Gene Therapy: Scientific, Quality, and Regulatory Rationale for a Technology Transfer Campaign

Kishan Rajput, Peivand Pirouzi, Pruthvirajsinh Sindha, Sukhpreet Singh Maan et al.
Zenodo (CERN European Organization for Nuclear Research)
Virus-based gene therapy research
article

Second-Source GMP Drug Substance Supply for a Systemically Administered AAV Gene Therapy: Scientific, Quality, and Regulatory Rationale for a Technology Transfer Campaign

Kishan Rajput, Peivand Pirouzi, Pruthvirajsinh Sindha, Sukhpreet Singh Maan, Vraj Modi
article en

Abstract

Adeno-associated virus (AAV) vectors have made systemic gene replacement feasible for diseases of muscle and other tissues, but the doses required, commonly in the range of 10 to the power of 13 to 10 to the power of 14 vector genomes per kilogram, convert every patient into a manufacturing problem. This article develops the scientific, quality, and regulatory rationale for qualifying a second drug substance manufacturing site for a hypothetical licensed, systemically administered AAV gene therapy produced by transient transfection of suspension HEK293 cells. It reviews why the payload problem led to engineered transgenes, how AAV manufacturing science defines the critical quality attributes that govern a site transfer (full-to-empty capsid ratio, residual nucleic acids, potency), and what ICH Q5E, FDA comparability guidance, and 21 C.F.R. 601.12 require of a manufacturing change to a licensed biologic. Four alternatives are compared, and a technology transfer with three conformance lots is shown to be the proportionate next step. A companion article converts this rationale into a request for proposal.Keywords: AAV gene therapy; drug substance; second-source manufacturing; comparability; ICH Q5E; potency assurance; capsid quality

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Second-Source GMP Drug Substance Supply for a Systemically Administered AAV Gene Therapy: Scientific, Quality, and Regulatory Rationale for a Technology Transfer Campaign — Kishan Rajput, Peivand Pirouzi, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS